[…]
Publication Programs: Trem-cel
Tandem Meetings – 2024 – Encore Poster Presentation 310
Trem-cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity During Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT) […]
Read More… from Tandem Meetings – 2024 – Encore Poster Presentation 310
ASH – ORAL PRESENTATION – 483
Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT) […]
HSCT² – 2023 – ORAL PRESENTATION
Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk AML and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) post-hematopoietic cell transplant (HCT) maintenance […]
Molecular Therapy: Methods & Clinical Development – Peer-Reviewed Manuscript
Development of a Gene Edited Next-Generation Hematopoietic Cell Transplant to Enable Acute Myeloid Leukemia Treatment by Solving Off-Tumor Toxicity […]
Read More… from Molecular Therapy: Methods & Clinical Development – Peer-Reviewed Manuscript
EHA – 2023 – Poster Presentation P1396
CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT) and Tolerate Post-HCT GemtuzumabOzogamicin(GO) Without Cytopenias […]
EBMT Annual Meeting – 2023 – Poster Presentation P249
Initial First-In-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplantation (HCT) and Tolerate Post-HCT Gemtuzumab Ozogamicin (GO) without Cytopenias […]
Read More… from EBMT Annual Meeting – 2023 – Poster Presentation P249
Tandem Meetings – 2023 – Poster Presentation LBA14
Initial First-In-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT) and Tolerate Post-HCT Gemtuzumab Ozogamicin (GO) without Cytopenias […]
Read More… from Tandem Meetings – 2023 – Poster Presentation LBA14
Cell & Gene – White Paper
Leveraging Human Genetics To Advance Cell Therapies For Treatment Of Blood Cancers […]